77-39-4
77-39-4
Chemical Structure
Cycrimine
- No. CAS: 77-39-4
- Formula:C19H29NO
- Molecular Weight:287.44
IUPAC Name: 1-cyclopentyl-1-phenyl-3-(piperidin-1-yl)propan-1-ol
InChIKey: SWRUZBWLEWHWRI-UHFFFAOYSA-N
SMILES: OC(C1CCCC1)(C2=CC=CC=C2)CCN3CCCCC3
Biological Activity: Cycrimine is an orally active muscarinic cholinergic receptor (mAChR) M1 antagonist, reduces the acetylcholine levels in parkinson model. Cycrimine shows antispasmodic activity, can be used in studies of behavioral and mental disorder[1][2][3][4].
| Referencia número | Nombre del producto | Pureza | Descripciòn | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cycrimine | 99.85% | Cycrimine is an orally active muscarinic cholinergic receptor (mAChR) M1 antagonist, reduces the acetylcholine levels in parkinson model. Cycrimine shows antispasmodic activity, can be used in studies of behavioral and mental disorder. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DAC 5945 | DAC 5945 is a potent muscarinic antagonist in the airways than in the heart, with pKi values of 8.3 and 7.52 for M1 and M2, respectively. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Biperiden hydrochloride | 99.26% | Biperiden (KL 373) hydrochloride is a non-selective muscarinic receptor antagonist that competitively binds to M1 muscarinic receptors, thereby inhibiting acetylcholine and enhancing dopamine signaling in the central nervous system. Biperiden hydrochloride has the potential for the research of Parkinson's disease and other related psychiatric disorders. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Biperiden | 99.11% | Biperiden (KL 373) is a non-selective muscarinic receptor antagonist that competitively binds to M1 muscarinic receptors, thereby inhibiting acetylcholine and enhancing dopamine signaling in the central nervous system. Biperiden has the potential for the research of Parkinson's disease and other related psychiatric disorders. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Triperiden | 99.88% | Triperiden is an inhibitor of influenza virus multiplication. Triperiden targets the haemagglutinin of fowl plague virus (FPV) for antiviral activity and acts by inhibiting the conformational change in the haemagglutinin at acid pH. Triperiden is also anticholinergic anti-parkinsonism agent. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Trihexyphenidyl hydrochloride | 99.44% | Trihexyphenidyl hydrochloride is a selective and orally active M1 muscarinic receptor antagonist with an IC50 of 3.7 nM for rat cerebral cortex M1 muscarinic receptors. Trihexyphenidyl hydrochloride modulates cholinergic activity, countering acetylcholine supersensitivity in neural pathways. Trihexyphenidyl hydrochloride improves movement disorder, inhibits McN-A-343 (HY-107648)-induced pressor responses, vagally-induced bradycardia and vasodilatation. Trihexyphenidyl hydrochloride can be used for the research of Parkinson's disease.. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Trihexyphenidyl | Trihexyphenidyl is a selective and orally active M1 muscarinic receptor antagonist with an IC50 of 3.7 nM for rat cerebral cortex M1 muscarinic receptors. Trihexyphenidyl modulates cholinergic activity, countering acetylcholine supersensitivity in neural pathways. Trihexyphenidyl improves movement disorder, inhibits McN-A-343 (HY-107648)-induced pressor responses, vagally-induced bradycardia and vasodilatation. Trihexyphenidyl can be used for the research of Parkinson's disease.. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pridinol | Pridinol is an orally active, blood-brain permeable, muscarinic acetylcholine receptor (mAChR)-directed muscle relaxant. Pridinol reduces the conduction of impulses to spinal motor neurons and exerts muscle relaxant activity. Pridinol inhibits skeletal muscle contractures in diseases of both central and peripheral origin and can be used in research in the field of musculoskeletal diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Procyclidine hydrochloride | 98.11% | Procyclidine (Tricyclamol, (±)-Procyclidine) hydrochloride , an anticholinergic agent, is a muscarinic receptor antagonist that also has the properties of an N-methyl-D-aspartate (NMDA) antagonist. Procyclidine hydrochloride can be used in studies of Parkinson's disease and related psychiatric disorders such as Soman-induced epilepsy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Procyclidine | Procyclidine (Tricyclamol; (±)-Procyclidine), an anticholinergic agent, is a muscarinic receptor antagonist that also has the properties of an N-methyl-D-aspartate (NMDA) antagonist. Procyclidine can be used in studies of Parkinson's disease and related psychiatric disorders such as Soman-induced epilepsy. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tridihexethyl chloride | 96.45% | Tridihexethyl (Pathilon) chloride is an orally active anticholinergic agent and mAChR antagonist, shows activities of antimuscarinic and anticholinergic. Tridihexethyl chloride shows pronounced antispasmodic and antisecretory effects on the gastrointestinal tract. Tridihexethyl chloride can be used in studies of peptic ulcer disease and acquired nystagmus . | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. David T. CHAU. Methods of treating behaviorial and/or mental disorders. WO2014176460A1.
- [2]. Marzoughi S, et al. Tardive neurotoxicity of anticholinergic drugs: A review. J Neurochem. 2021 Sep;158(6):1334-1344. [Content Brief]
- [3]. Tacke, et al. Syntheses and pharmacological characterization of achiral and chiral enantiopure C/Si/Ge-analogous derivatives of the muscarinic antagonist cycrimine: a study on C/Si/Ge bioisosterism. Journal of organometallic chemistry 640.1-2 (2001): 140-
- [4]. MAGEE KR, et al. Antispasmodic compound 08958 in treatment of paralysis agitans. J Am Med Assoc. 1953 Oct 24;153(8):715-8. [Content Brief]
